Investing.com -- Intellia Therapeutics (NASDAQ:NTLA) stock fell 19% after the market close Wednesday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on the company’s Phase 3 ...
Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback